Exercise Training and Inflammatory Mediators in COPD

December 18, 2019 updated by: Acheche Amal, Faculty of Medicine, Sousse

Effect of Exercise Training on Inflammatory Mediators in COPD

Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020[1]. COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversable[2].

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020. COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversable.Not only the long-term exposition to noxious particles and gases contributes to the development of COPD, but also so many others factors such as genetics and cigarette smoking. It has been shown that cigarettes are harmful and contributed to different extra pulmonary disorders. Indeed, it induced a systemic inflammation that was considered as a key process in the pathogenesis of COPD and triggered the activation of inflammatory cells and an abnormal increase of circulating cytokines such as CRP, interleukin (IL6), IL8, tumor necrosis factor alpha (TNF alpha) and leptin.

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Tunisia
      • Sousse, Tunisia, 4002
        • Amal Acheche

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • COPD diagnosed by pulmonary function testing
  • Clinically stable
  • Abscence of other obstructive diseases
  • Signed written consent

Exclusion Criteria:

  • Neuromuscular diseases -Severe psychiatric, neurologic or musculoskeletal conditions and /or instable--- --
  • cardiovascular diseases.
  • Contre-indications to physical therapy
  • Acute exacerbations a month before the intervention

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ET
Active Comparator: ET Endurance training were prformed. Intensity was gradually increased.
Other: Endurance Training ET
Endurance training were prformed. Intensity was gradually increased.
Other: RT
Resistance training were prformed. Intensity was gradually increased.
Other: Resistance Training RT
Resistance training were prformed. Intensity was gradually increased.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Enzyme linked immunosorbent assay for serum cytokines levels change
Time Frame: Baseline, 6 months
The interleukines were determined by ELISA assays with commercial kits
Baseline, 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Faculty of Medicine, Sousse

Investigators

  • Principal Investigator: Amal Acheche, Phd, Faculty of Medicine of Sousse Sousse, Tunisia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2019

Primary Completion (Actual)

April 17, 2019

Study Completion (Actual)

April 27, 2019

Study Registration Dates

First Submitted

February 21, 2019

First Submitted That Met QC Criteria

February 22, 2019

First Posted (Actual)

February 25, 2019

Study Record Updates

Last Update Posted (Actual)

December 20, 2019

Last Update Submitted That Met QC Criteria

December 18, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • COPD and exercise

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on Endurance Training ET

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe